Resolve Therapeutics Missed the Headline Endpoint - Then Built a Smarter Trial From the Miss

The tiny Miami biotech spent years testing a simple idea: digest inflammatory RNA instead of suppressing the immune system. Its first big readouts were messy - and the useful part was hiding inside the miss.